← back to search

Bernard M.J. Uitdehaag

Amsterdam University Medical Centers · NL
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Amyotrophic Lateral Sclerosis Research, and Systemic Lupus Erythematosus Research.
h-index
83
citations
37,276
works
607
NIH funding
primary concept
email

Recent publications

Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy
Journal of Neurology 2025cited by 5position: middledoi
Cognitive test performance and disease progression in primary and secondary progressive MS: An analysis of the SPRINT-MS study
Multiple Sclerosis Journal 2025cited by 3position: middledoi
Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis
Neurology 2024cited by 7position: middledoi
The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions
Multiple Sclerosis and Related Disorders 2022cited by 40position: middledoi
The nine hole peg test as an outcome measure in progressive MS trials
Multiple Sclerosis and Related Disorders 2022cited by 13position: middledoi
Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis
Neurology 2021cited by 40position: middledoi
Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?
European Journal of Neurology 2021cited by 24position: middledoi
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis
Multiple Sclerosis Journal 2021cited by 16position: middledoi
Longitudinal Assessment of Multiple Sclerosis with the Brain‐Age Paradigm
Annals of Neurology 2020cited by 151position: middledoi
Personalized extended interval dosing of natalizumab in MS
Neurology 2020cited by 54position: middledoi
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis
Neurology 2020cited by 52position: middledoi
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis
Neurology 2020cited by 41position: middledoi
The sequence of structural, functional and cognitive changes in multiple sclerosis
NeuroImage Clinical 2020cited by 39position: middledoi
Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study
NeuroImage Clinical 2020cited by 33position: middledoi
Multiple Sclerosis Data Alliance – A global multi-stakeholder collaboration to scale-up real world data research
Multiple Sclerosis and Related Disorders 2020cited by 24position: middledoi
Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data
Neurology 2019cited by 93position: middledoi
Predicting clinical progression in multiple sclerosis after 6 and 12 years
European Journal of Neurology 2019cited by 58position: middledoi
Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?
Multiple Sclerosis Journal 2019cited by 39position: middledoi
Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets
Multiple Sclerosis Journal 2019cited by 26position: middledoi
Natural History of Vanishing White Matter
Annals of Neurology 2018cited by 119position: middledoi
Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis
JAMA Neurology 2018cited by 46position: middledoi
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
The Lancet Neurology 2017cited by 7,854position: middledoi
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
Multiple Sclerosis Journal 2017cited by 64position: middledoi
Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS
Journal of Neurology Neurosurgery & Psychiatry 2017cited by 44position: middledoi
Comparative utility of disability progression measures in PPMS
Neurology Neuroimmunology & Neuroinflammation 2017cited by 19position: middledoi
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet 2016cited by 449position: middledoi
Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study
Journal of Neurology 2016cited by 136position: middledoi
Recommendations for observational studies of comorbidity in multiple sclerosis
Neurology 2016cited by 81position: middledoi
The challenge of comorbidity in clinical trials for multiple sclerosis
Neurology 2016cited by 60position: middledoi
The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink
Journal of Thrombosis and Haemostasis 2014cited by 52position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Gary Cutter · Epilepsy Foundation10 papers (2017–2025)Jop Mostert · University of Alabama at Birmingham10 papers (2019–2025)Marcus Koch · University of Calgary10 papers (2017–2025)Frederik Barkhof · The Queen's Medical Research Institute9 papers (2017–2020)James D. Bowen · Toronto Public Health7 papers (2020–2025)Mike P. Wattjes · Humboldt-Universität zu Berlin7 papers (2017–2020)Joep Killestein · Palacký University Olomouc7 papers (2016–2020)Pavle Repovic · University of Alabama at Birmingham7 papers (2020–2025)Eva Strijbis · University of Alabama at Birmingham5 papers (2021–2025)Birgit I. Lissenberg‐Witte · University Medical Center Utrecht4 papers (2018–2020) · 4 papers (2019–2020)Jacynthe Comtois · Bausch Health (Canada)4 papers (2022–2025)Fred Lublin · Icahn School of Medicine at Mount Sinai3 papers (2016–2021)Jeroen J.G. Geurts · Amsterdam Neuroscience3 papers (2019–2020) · 3 papers (2019–2020)Marloes T. Bazelier · Utrecht University3 papers (2012–2014)Lisanne J. Balk · Amsterdam UMC Location Vrije Universiteit Amsterdam3 papers (2016–2019)Jerry S. Wolinsky · The University of Texas Health Science Center3 papers (2016–2021)Frank de Vries · Utrecht University3 papers (2012–2014)Gavin Giovannoni · Royal London Hospital for Integrated Medicine2 papers (2017–2020)